Abstract
The increase in the human lifespan has not been paralleled by an increase in healthy life. With the increase in the proportion of the aged population, there has been a natural increase in the prevalence of age-related disorders, such as Alzheimer’s disease, type 2 diabetes mellitus, frailty, and various other disorders. A continuous rise in these conditions could lead to a widespread medical and social burden. There are now considerable efforts underway to address these deficits in preclinical and clinical studies, which include the use of better study cohorts, longitudinal designs, improved translation of data from preclinical models, multi-omics profiling, identification of new biomarker candidates and refinement of computational tools and databases containing relevant information. Such efforts will support future interdisciplinary studies and help to identify potential new targets that are amenable to therapeutic approaches such as pharmacological interventions to increase the human healthspan in parallel with the lifespan.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Olshansky SJ, Carnes BA (2019) Inconvenient truths about human longevity. J Gerontol A Biol Sci Med Sci 74(Suppl 1):S7–S12. https://doi.org/10.1093/gerona/glz098
https://esa.un.org/unpd/wpp/Publications/Files/WPP2017_KeyFindings.pdf
Cutler RG, Mattson MP (2006) The adversities of aging. Ageing Res Rev 5(3):221–238
Kirkland JL, Peterson C (2009) Healthspan, translation, and new outcomes for animal studies of aging. J Gerontol A Biol Sci Med Sci 64(2):209–212
Lai WF, Chan ZC (2011) Beyond sole longevity: a social perspective on healthspan extension. Rejuvenation Res 14(1):83–88
Seals DR, Justice JN, LaRocca TJ (2016) Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity. J Physiol 594(8):2001–2024
Olshansky SJ, Goldman DP, Zheng Y, Rowe JW (2009) Aging in America in the twenty-first century: demographic forecasts from the MacArthur Foundation research network on an aging society. Milbank Q 87(4):842–862
Harper S (2014) Economic and social implications of aging societies. Science 346(6209):587–591
Andersen SL, Sebastiani P, Dworkis DA, Feldman L, Perls TT (2012) Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span. J Gerontol A Biol Sci Med Sci 67(4):395–405
Crimmins EM, Beltrán-Sánchez H (2011) Mortality and morbidity trends: is there compression of morbidity? J Gerontol B Psychol Sci Soc Sci 66(1):75–86
https://apps.who.int/iris/bitstream/handle/10665/311696/WHO-DAD-2019.1-eng.pdf
Beltran-Sanchez H, Preston SH, Canudas-Romo V (2008) An integrated approach to cause-of-death analysis: cause-deleted life tables and decompositions of life expectancy. Demogr Res 19:1323. https://doi.org/10.4054/DemRes.2008.19.35
Coelho-Júnior HJ, Milano-Teixeira L, Rodrigues B, Bacurau R, Marzetti E, Uchida M (2018) Relative protein intake and physical function in older adults: a systematic review and meta-analysis of observational studies. Nutrients 10(9):pii: E1330. https://doi.org/10.3390/nu10091330
Govindaraju T, Sahle BW, McCaffrey TA, McNeil JJ, Owen AJ (2018) Dietary patterns and quality of life in older adults: a systematic review. Nutrients 10(8):pii: E971. https://doi.org/10.3390/nu10080971
Klímová B, Vališ M (2018) Nutritional interventions as beneficial strategies to delay cognitive decline in healthy older individuals. Nutrients 10(7):pii: E905. https://doi.org/10.3390/nu10070905
Blanchet S, Chikhi S, Maltais D (2018) The benefits of physical activities on cognitive and mental health in healthy and pathological aging. Geriatr Psychol Neuropsychiatr Vieil 16(2):197–205
Fisher JP, Steele J, Gentil P, Giessing J, Westcott WL (2017) A minimal dose approach to resistance training for the older adult; the prophylactic for aging. Exp Gerontol 99:80–86
Schnohr P, O’Keefe JH, Lange P, Jensen GB, Marott JL (2017) Impact of persistence and non-persistence in leisure time physical activity on coronary heart disease and all-cause mortality: the Copenhagen City heart study. Eur J Prev Cardiol 24(15):1615–1623
Shadyab AH, LaMonte MJ, Kooperberg C, Reiner AP, Carty CL, Manini TM (2017) Association of accelerometer-measured physical activity with leukocyte telomere length among older women. J Gerontol A Biol Sci Med Sci 72(11):1532–1537
https://www.who.int/tobacco/global_report/2011/implementation_effective_measures.pdf
Murray CJ, Lopez AD (2013) Measuring the global burden of disease. N Engl J Med 369(5):448–457
Hagberg B, Samuelsson G (2008) Survival after 100 years of age: a multivariate model of exceptional survival in Swedish centenarians. J Gerontol A Biol Sci Med Sci 63(11):1219–1226
Rajpathak SN, Liu Y, Ben-David O, Reddy S, Atzmon G, Crandall J et al (2011) Lifestyle factors of people with exceptional longevity. J Am Geriatr Soc 59(8):1509–1512
Levine M, Crimmins E (2014) Not all smokers die young: a model for hidden heterogeneity within the human population. PLoS One 9(2):e87403. https://doi.org/10.1371/journal.pone.0087403
Reid MC, Boutros NN, O’Connor PG, Cadariu A, Concato J (2002) The health-related effects of alcohol use in older persons: a systematic review. Subst Abus 23(3):149–164
Kloner RA, Rezkalla SH (2007) To drink or not to drink? That is the question. Circulation 116(11):1306–1317
Giles LC, Glonek GF, Luszcz MA, Andrews GR (2005) Effect of social networks on 10 year survival in very old Australians: the Australian longitudinal study of aging. J Epidemiol Community Health 59(7):574–579
Manzoli L, Villari P, Pirone GM, Boccia A (2007) Marital status and mortality in the elderly: a systematic review and meta-analysis. Soc Sci Med 64(1):77–94
Holt-Lunstad J, Smith TB, Layton JB (2010) Social relationships and mortality risk: a meta-analytic review. PLoS Med 7:e1000316. https://doi.org/10.1371/journal.pmed.1000316
Cohen S (2004) Social relationships and health. Am Psychol 59(8):676–684
Njajou OT, Hsueh WC, Blackburn EH, Newman AB, Wu SH, Li R et al (2009) Association between telomere length, specific causes of death, and years of healthy life in health, aging, and body composition, a population-based cohort study. J Gerontol A Biol Sci Med Sci 64(8):860–864
Kim S, Bi X, Czarny-Ratajczak M, Dai J, Welsh DA, Myers L et al (2012) Telomere maintenance genes SIRT1 and XRCC6 impact age-related decline in telomere length but only SIRT1 is associated with human longevity. Biogerontology 13(2):119–131
Bendix L, Gade MM, Staun PW, Kimura M, Jeune B, Hjelmborg JV et al (2011) Leukocyte telomere length and physical ability among Danish twins age 70+. Mech Ageing Dev 132(11–12):568–572
Risques RA, Arbeev KG, Yashin AI, Ukraintseva SV, Martin GM, Rabinovitch PS et al (2010) Leukocyte telomere length is associated with disability in older U.S. population. J Am Geriatr Soc 58(7):1289–1298
Soerensen M, Thinggaard M, Nygaard M, Dato S, Tan Q, Hjelmborg J et al (2012) Genetic variation in TERT and TERC and human leukocyte telomere length and longevity: a cross-sectional and longitudinal analysis. Aging Cell 11(2):223–227
Atzmon G, Cho M, Cawthon RM, Budagov T, Katz M, Yang X et al (2010) Evolution in health and medicine Sackler colloquium: genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians. Proc Natl Acad Sci U S A 107(Suppl 1):1710–1717
Deelen J, Uh HW, Monajemi R, van Heemst D, Thijssen PE, Bohringer S et al (2013) Gene set analysis of GWAS data for human longevity highlights the relevance of the insulin/IGF-1 signaling and telomere maintenance pathways. Age (Dordr) 35(1):235–249
Mecocci P, Boccardi V, Cecchetti R, Bastiani P, Scamosci M, Ruggiero C et al (2018) A Long journey into aging, brain aging, and Alzheimer’s disease following the oxidative stress tracks. J Alzheimers Dis 62(3):1319–1335
Cummings JL, Cole G (2002) Alzheimer disease. JAMA 287(18):2335–2338
Billingsley ML, Kincaid RL (1997) Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 323(Pt 3):577–559
Berg L, McKeel DW Jr, Miller JP, Baty J, Morris JC (1993) Neuropathological indexes of Alzheimer’s disease in demented and non demented persons aged 80 years and older. Arch Neurol 50(4):349–358
Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP et al (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 60(9):1495–1500
Poprac P, Jomova K, Simunkova M, Kollar V, Rhodes CJ, Valko M (2017) Targeting free radicals in oxidative stress-related human diseases. Trends Pharmacol Sci 38(7):592–607
Oliver DMA, Reddy PH (2019) Small molecules as therapeutic drugs for Alzheimer’s disease. Mol Cell Neurosci 96:47–62
Rentz DM, Parra Rodriguez MA, Amariglio R, Stern Y, Sperling R, Ferris S (2013) Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective review. Alzheimers Res Ther 5:58. https://doi.org/10.1186/alzrt222. eCollection 2013
Rentz DM, Amariglio RE, Becker JA, Frey M, Olson LE, Frishe K et al (2011) Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia 49(9):2776–2783. https://doi.org/10.1016/j.neuropsychologia.2011.06.006
Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ (2017) Biomarkers for the early detection and progression of Alzheimer’s disease. Neurotherapeutics 14(1):35–53
Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Bozinosvski S et al (2017) A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer’s disease: the PBT2-204 IMAGINE study. Alzheimers Dement (N Y) 3(4):622–635
Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM et al (2018) Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study. PLoS Med 15(1):e1002482. https://doi.org/10.1371/journal.pmed.1002482
Nabers A, Perna L, Lange J, Mons U, Schartner J, Güldenhaupt J et al (2018) Amyloid blood biomarker detects Alzheimer’s disease. EMBO Mol Med 10(5):pii: e8763. https://doi.org/10.15252/emmm.201708763
Doraiswamy PM (2002) Non-cholinergic strategies for treating and preventing Alzheimer’s disease. CNS Drugs 16(12):811–824
Doggrell S (2003) Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer’s disease? Expert Opin Pharmacother 4(10):1857–1860
Modrego PJ (2010) Depression in Alzheimer’s disease. Pathophysiology, diagnosis, and treatment. J Alzheimers Dis 21(4):1077–1087
El Haj M, Gallouj K, Antoine P (2017) Google calendar enhances prospective memory in Alzheimer’s disease: a case report. J Alzheimers Dis 57(1):285–291
Brown EL, Ruggiano N, Li J, Clarke PJ, Kay ES, Hristidis V (2017) Smartphone-based health technologies for dementia care: opportunities, challenges, and current practices. J Appl Gerontol Aug 1:733464817723088. https://doi.org/10.1177/0733464817723088
Brown BM, Peiffer JJ, Sohrabi HR, Mondal A, Gupta VB, Rainey-Smith SR et al (2012) Intense physical activity is associated with cognitive performance in the elderly. Transl Psychiatry 2:e191. https://doi.org/10.1038/tp.2012.118
Huntley JD, Gould RL, Liu K, Smith M, Howard RJ (2015) Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression. BMJ Open 5(4):e005247. https://doi.org/10.1136/bmjopen-2014-005247
Jhee S, Shiovitz T, Crawford AW, Cutler NR (2001) Beta-amyloid therapies in Alzheimer’s disease. Expert Opin Investig Drugs 10(4):593–605
Pollack SJ, Lewis H (2005) Secretase inhibitors for Alzheimer’s disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 6(1):35–47
Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K (2017) Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38(9):1205–1235
Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA (2011) Insulin-resistant brain state: the culprit in sporadic Alzheimer’s disease? Ageing Res Rev 10(2):264–273
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32(9):1626–1633
Cheng H, Shang Y, Jiang L, Shi TL, Wang L (2016) The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer’s disease and mild-to-moderate Alzheimer’s disease: a meta-analysis. Int J Neurosci 126(4):299–307
Wisniewski T, Drummond E (2016) Developing therapeutic vaccines against Alzheimer’s disease. Expert Rev Vaccines 15(3):401–415
Hung SY, Fu WM (2017) Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci 24(1):47. https://doi.org/10.1186/s12929-017-0355-7
Grüninger F (2015) Invited review: drug development for tauopathies. Neuropathol Appl Neurobiol 41(1):81–96
Godyń J, Jończyk J, Panek D, Malawska B (2016) Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep 68(1):127–138
Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R et al (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 16(2):123–134
Schultz BG, Patten DK, Berlau DJ (2018) The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener 7:5. https://doi.org/10.1186/s40035-018-0110-3
Li HH, Lin CL, Huang CN (2018) Neuroprotective effects of statins against amyloid β-induced neurotoxicity. Neural Regen Res 13(2):198–206
Chu CS, Tseng PT, Stubbs B, Chen TY, Tang CH, Li DJ et al (2018) Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. Sci Rep 8(1):5804. https://doi.org/10.1038/s41598-018-24248-8
Figueiredo-Pereira ME, Corwin C, Babich J (2016) Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration. Ann N Y Acad Sci 1363:125–137
Camargo CHF, Justus FF, Retzlaff G, Blood MRY, Schafranski MD (2015) Action of anti-TNF-α drugs on the progression of Alzheimer’s disease: a case report. Dement Neuropsychol 9(2):196–200
Butchart J, Brook L, Hopkins V, Teeling J, Püntener U, Culliford D et al (2015) Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology 84(21):2161–2168
Mazzanti G, Di Giacomo S (2016) Curcumin and resveratrol in the management of cognitive disorders: what is the clinical evidence? Molecules 21(9):pii: E1243. https://doi.org/10.3390/molecules21091243
Barbara R, Belletti D, Pederzoli F, Masoni M, Keller J, Ballestrazzi A et al (2017) Novel Curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt Abeta aggregates. Int J Pharm 526(1–2):413–424
Liu QP, Wu YF, Cheng HY, Xia T, Ding H, Wang H et al (2016) Habitual coffee consumption and risk of cognitive decline/dementia: a systematic review and meta-analysis of prospective cohort studies. Nutrition 32(6):628–636
Thaipisuttikul P, Galvin JE (2012) Use of medical foods and nutritional approaches in the treatment of Alzheimer’s disease. Clin Pract (Lond) 9(2):199–209
Farina N, Rusted J, Tabet N (2014) The effect of exercise interventions on cognitive outcome in Alzheimer’s disease: a systematic review. Int Psychogeriatr 26(1):9–18
Bertram S, Brixius K, Brinkmann C (2016) Exercise for the diabetic brain: how physical training may help prevent dementia and Alzheimer’s disease in T2DM patients. Endocrine 53(2):350–363
Shankle WR, Hara J, Barrentine LW, Curole MV (2016) CerefolinNAC therapy of Hyperhomocysteinemia delays cortical and White matter atrophy in Alzheimer’s disease and cerebrovascular disease. J Alzheimers Dis 54(3):1073–1084
Ohnuma T, Toda A, Kimoto A, Takebayashi Y, Higashiyama R, Tagata Y et al (2016) Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study. Clin Interv Aging 11:29–36
Berti V, Walters M, Sterling J, Quinn CG, Logue M, Andrews R et al (2018) Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. Neurology. https://doi.org/10.1212/WNL.0000000000005527
Rendeiro C, Rhodes JS (2018) A new perspective of the hippocampus in the origin of exercise-brain interactions. Brain Struct Funct 223:2527. https://doi.org/10.1007/s00429-018-1665-6
Devenney KE, Sanders ML, Lawlor B, Olde Rikkert MGM, Schneider S, NeuroExercise Study Group (2017) The effects of an extensive exercise programme on the progression of mild cognitive impairment (MCI): study protocol for a randomised controlled trial. BMC Geriatr 17(1):75. https://doi.org/10.1186/s12877-017-0457-9
Karssemeijer EG, Bossers WJ, Aaronson JA, Kessels RP, Olde Rikkert MG (2017) The effect of an interactive cycling training on cognitive functioning in older adults with mild dementia: study protocol for a randomized controlled trial. BMC Geriatr 17(1):73. https://doi.org/10.1186/s12877-017-0464-x
https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf?sequence=1
NCD Risk Factor Collaboration (NCD-RisC), Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M et al (2016) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387(10027):1513–1530
Seuring T, Archangelidi O, Suhrcke M (2015) The economic costs of type 2 diabetes: a global systematic review. PharmacoEconomics 33(8):811–831
Rauseo A, Pacilli A, Palena A, De Cosmo SA (2010) Management of type 2 diabetes in geriatric patients. J Nephrol 23(Suppl 15):S72–S79
Strain WD, Hope SV, Green A, Kar P, Valabhji J, Sinclair AJ (2018) Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. Diabet Med 35(7):838–845
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403
Diabetes Prevention Program Research Group; Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ et al (2009) 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet 374(9702):1677–1686
Hales CN, Barker DJ (1992) Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 35(5):595–601
Nielsen JH, Haase TN, Jaksch C, Nalla A, Søstrup B, Nalla AA et al (2014) Impact of fetal and neonatal environment on beta cell function and development of diabetes. Acta Obstet Gynecol Scand 93(11):1109–1122
Vaag A, Brons C, Gillberg L, Hansen NS, HjortL AGP et al (2014) Genetic, nongenetic and epigenetic risk determinants indevelopmental programming of type 2 diabetes. Acta Obstet Gynecol Scand 93(11):1099–1108
Coope A, Torsoni AS, Velloso L (2015) Mechanisms in endocrinology: metabolic and inflammatory pathways on the pathogenesis of type 2 diabetes. Eur J Endocrinol 174(5):R175–R187
DeFronzo RA (1992) Pathogenesis of type2 (non-insulindependent) diabetes mellitus: a balanced overview. Diabetologia 35(4):389–397
Perseghin G, Ghosh S, Gerow K, Shulman GI (1997) Metabolic defects in lean non diabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 46(6):1001–1009
Henriksen JE, Levin K, Thye-Rønn P, Alford F, Hother-Nielsen O, Holst JJ, Beck-Nielsen H (2000) Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients. Diabetes 49(7):1209–1218
Dimas AS, Lagou V, Barker A, Knowles JW, Mägi R, Hivert MF et al (2014) Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 63(6):2158–2171
Domingueti CP, Dusse LM, Carvalho MD, de Sousa LP, Gomes KB, Fernandes AP (2015) Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complicat 30(4):738–745
Pruzin JJ, Nelson PT, Abner EL, Arvanitakis Z (2018) Review: relationship of type 2 diabetes to human brain pathology. Neuropathol Appl Neurobiol 44(4):347–362
Al Haj Ahmad RM, Al-Domi HA (2018) Thinking about brain insulin resistance. Diabetes Metab Syndr 12(6):1091–1094
Zhang S, Jamaspishvili E, Tong H, Chen Y, Zhou Z, Sun L et al (2019) East Asian Genome-wide association study derived loci in relation to type 2 diabetes in the Han Chinese population. Acta Biochim Pol. https://doi.org/10.18388/abp.2018_2632
FIND Consortium, Guan M, Keaton JM, Dimitrov L, Hicks PJ, Xu J et al (2019) Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans. Hum Genomics 13(1):21. https://doi.org/10.1186/s40246-019-0205-7
Tang Y, Lenzini PA, Busui RP, Ray PR, Campbell H, Perkins BA et al (2019) A genetic locus on chromosome 2q24 predicting peripheral neuropathy risk in type 2 diabetes: results from the ACCORD and BARI 2D studies. Diabetes 68(8):1649–1662. https://doi.org/10.2337/db19-0109
Azzam SK, Osman WM, Lee S, Khalaf K, Khandoker AH, Almahmeed W et al (2019) Genetic associations with diabetic retinopathy and coronary artery disease in Emirati patients with Type-2 diabetes mellitus. Front Endocrinol (Lausanne) 10:283. https://doi.org/10.3389/fendo.2019.00283
Chung SJ, Kim MJ, Kim J, Ryu HS, Kim YJ, Kim SY et al (2015) Association of type 2 diabetes GWAS loci and the risk of Parkinson’s and Alzheimer’s diseases. Parkinsonism Relat Disord 21(12):1435–1440
Li Z, Chen P, Chen J, Xu Y, Wang Q, Li X et al (2018) Glucose and insulin-related traits, type 2 diabetes and risk of schizophrenia: a Mendelian randomization study. EBioMedicine 34:182–188
Steyn NP, Mann J, Bennett PH, Temple N, Zimmet P, Tuomilehto J et al (2004) Diet, nutrition and the prevention of type 2 diabetes. Public Health Nutr 7(1A):147–165
Mattei J, Malik V, Wedick NM, Hu FB, Spiegelman D, Willett WC et al (2015) Reducing the global burden of type 2 diabetes by improving the quality of staple foods: the global nutrition and epidemiologic transition initiative. Glob Health 11:23. https://doi.org/10.1186/s12992-015-0109-9
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P (2001) Prevention of type 2 diabetes mellitus by changes in life style among subjects with impaired glucose tolerance. N Engl J Med 344(18):1343–1350
Sundsten T, Eberhardson M, Göransson M, Bergsten P (2006) The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci 4(22):22. https://doi.org/10.1186/1477-5956-4-22
Riaz S, Alam SS, Akhtar MW (2010) Proteomic identification of human serum biomarkers in diabetes mellitus type 2. J Pharm Biomed Anal 51(5):1103–1107
Bhonsle HS, Korwar AM, Chougale AD, Kote SS, Dhande NL, Shelgikar KM et al (2013) Proteomic study reveals downregulation of apolipoprotein A1 in plasma of poorly controlled diabetes: a pilot study. Mol Med Rep 7(2):495–498
Mao P, Wang D (2014) Top-down proteomics of a drop of blood for diabetes monitoring. J Proteome Res 13(3):1560–1569
Walford GA, Porneala BC, Dauriz M, Vassy JL, Cheng S, Rhee EP, Wang TJ, Meigs JB, Gerszten RE, Florez JC (2014) Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care 37(9):2508–2514
Floegel A, Stefan N, Yu Z, Mühlenbruch K, Drogan D, Joost HG et al (2013) Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 62(2):639–648
Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E et al (2011) Metabolite profiles and the risk of developing diabetes. Nat Med 17(4):448–453
Nawaz SS, Siddiqui K (2019) The emerging role of branch chain amino acids in the prediction of diabetes: a brief review. Curr Diabetes Rev 15. https://doi.org/10.2174/1573399815666190502113632
Padberg I, Peter E, González-Maldonado S, Witt H, Mueller M, Weis T et al (2014) A new metabolomic signature in type-2 diabetes mellitus and its pathophysiology. PLoS One 9:e85082. https://doi.org/10.1371/journal.pone.0085082
Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari A, Adam KP et al (2013) Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 62(5):1730–1737
Erion DM, Park HJ, Lee HY (2016) The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Rep 49(3):139–148
SUMMIT Consortium; Shore AC, Colhoun HM, Natali A, Palombo C, Khan F et al (2018) Use of vascular assessments and novel biomarkers to predict cardiovascular events in type 2 diabetes: the SUMMIT VIP study. Diabetes Care 41(10):2212–2219
EXAMINE Investigators, Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y et al (2019) Relation of serum and urine renal biomarkers to cardiovascular risk in patients with type 2 diabetes mellitus and recent acute coronary syndromes (from the EXAMINE trial). Am J Cardiol 123(3):382–391
Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al (2000) Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinoprilmicroalbuminuria (CALM) study. Br Med J 321(7274):1440–1444
Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20(8):1813–1821
van der Velde M, Halbesma N, de Charro FT, Bakker SJ, de Zeeuw D, de Jong PE et al (2009) Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol 20(4):852–862
Kazumi T, Hozumi T, Ishida Y, Ikeda Y, Kishi K, Hayakawa M et al (1999) Increased urinary transferrin excretion predicts microalbuminuria in patients with type 2 diabetes. Diabetes Care 22(7):1176–1180
Narita T, Hosoba M, Kakei M, Ito S (2006) Increased urinary excretions of immunoglobulin G, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care 29(1):142–144
Araki S, Haneda M, Koya D, Sugimoto T, Isshiki K, Chin-Kanasaki M et al (2007) Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. Diabetologia 50(4):867–873
Hanai K, Babazono T, Nyumura I, Toya K, Tanaka N, Tanaka M et al (2009) Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 24(6):1884–1888
Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk CG, Tarnow L et al (2008) Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in patients with type 2 diabetes and microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest 68(8):731–738
Liu J, Zhao Z, Willcox MD, Xu B, Shi B (2010) Multiplex bead analysis of urinary cytokines of type 2 diabetic patients with normo- and microalbuminuria. J Immunoassay Immunochem 31(4):279–289
Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R et al (2013) Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 24(11):1901–1912
Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH et al (2014) Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int 85(5):1214–1224
BEAt-DKD Consortium; Heinzel A, Kammer M, Mayer G, Reindl-Schwaighofer R, Hu K et al (2018) Validation of plasma biomarker candidates for the prediction of eGFR decline in patients with type 2 diabetes. Diabetes Care 41(9):1947–1954
Rodriguez-Romero V, Bergstrom RF, Decker BS, Lahu G, Vakilynejad M, Bies RR (2019) Prediction of nephropathy in type 2 diabetes: an analysis of the ACCORD trial applying machine learning techniques. Clin Transl Sci 12:519. https://doi.org/10.1111/cts.12647
https://apps.who.int/iris/bitstream/handle/10665/272437/WHO-FWC-ALC-17.2-eng.pdf
Cardiovascular Health Study Collaborative Research Group; Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146–M156
Rockwood K, Mitnitski A (2007) Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci 62(7):722–727
Brunner EJ, Shipley MJ, Ahmadi-Abhari S, Valencia Hernandez C, Abell JG, Singh-Manoux A et al (2018) Midlife contributors to socioeconomic differences in frailty during later life: a prospective cohort study. Lancet Public Health 3(7):e313–e322
Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS (2018) Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK biobank participants. Lancet Public Health 3(7):e323–e332
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K (2013) Frailty in elderly people. Lancet 381(9868):752–762
Santilli V, Bernetti A, Mangone M, Paoloni M (2014) Clinical definition of sarcopenia. Clin Cases Miner Bone Metab 11(3):177–180
Fried L, Walston J (1998) Frailty and failure to thrive. In: Hazzard WR, Blass JP, Ettinger WH Jr, Halter JB, Ouslander JG (eds) Principles of geriatric medicine and gerontology, vol 4th edn. McGraw-Hill Education (ISE Editions), New York, NY, pp 1387–1402. ISBN-10: 0071157549
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F et al (2010) Sarcopenia: European consensus on definition and diagnosis-report of the European working group on sarcopenia in older people. Age Ageing 39:412–423
Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G et al (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by special interest groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 29:154–159
Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB et al (2011) Sarcopenia: an undiagnosed condition in older adults—current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12:249–256
Rizzoli R, Reginster JY, Arnal JF, Bautmans I, Beaudart C, Bischoff-Ferrari H et al (2013) Quality of life in sarcopenia and frailty. Calcif Tissue Int 93(2):101–120
Beaudart C, McCloskey E, Bruyère O, Cesari M, Rolland Y, Rizzoli R et al (2016) Sarcopenia in daily practice: assessment and management. BMC Geriatr 16(1):170. https://doi.org/10.1186/s12877-016-0349-4
Rich MW, Shah AS, Vinson JM, Freedland KE, Kuru T, Sperry JC (1996) Iatrogenic congestive heart failure in older adults: clinical course and prognosis. J Am Geriatrics Soc 44(6):638–643
Ferrucci L, Cavazzini C, Corsi A, Bartali B, Russo CR, Lauretani F et al (2002) Biomarkers of frailty in older persons. J Endocrinol Investig 25(10 Suppl):10–15
Cardoso AL, Fernandes A, Aguilar-Pimentel JA, de Angelis MH, Guedes JR, Brito MA et al (2018) Towards frailty biomarkers: candidates from genes and pathways regulated in aging and age-related diseases. Ageing Res Rev 47:214–277
Peterson MD, Sen A, Gordon PM (2011) Influence of resistance exercise on lean body mass in aging adults: a meta-analysis. Med Sci Sport Exerc 43(2):249–258
Cruz-Jentoft AJ, Landi F, Schneider SM, Zúñiga C, Arai H, Boirie Y et al (2014) Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the international sarcopenia initiative (EWGSOP and IWGS). Age Ageing 43(6):748–759
von Berens Å, Fielding RA, Gustafsson T, Kirn D, Laussen J, Nydahl M et al (2018) Effect of exercise and nutritional supplementation on health-related quality of life and mood in older adults: the VIVE2 randomized controlled trial. BMC Geriatr 18(1):286. https://doi.org/10.1186/s12877-018-0976-z
Liao CD, Chen HC, Huang SW, Liou TH (2019) The role of muscle mass gain following protein supplementation plus exercise therapy in older adults with sarcopenia and frailty risks: a systematic review and meta-regression analysis of randomized trials. Nutrients 11(8):pii: E1713. https://doi.org/10.3390/nu11081713
Sahni S, Mangano KM, Hannan MT, Kiel DP, McLean RR (2015) Higher protein intake is associated with higher lean mass and quadriceps muscle strength in adult men and women. J Nutr 145:1569–1575
Genaro Pde S, Pinheiro Mde M, Szejnfeld VL, Martini LA (2015) Dietary protein intake in elderly women: association with muscle and bone mass. Nutr Clin Pract 30:283–289
Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE et al (2013) J Am Med Dir Assoc 14:542–559
Deer RR, Volpi E (2015) Protein intake and muscle function in older adults. Curr Opin Clin Nutr Metab Care 18:248–253
Buigues C, Fernández-Garrido J, Pruimboom L, Hoogland AJ, Navarro-Martínez R, Martínez-Martínez M et al (2016) Effect of a prebiotic formulation on frailty syndrome: a randomized, double-blind clinical trial. Int J Mol Sci 17(6):pii: E932. https://doi.org/10.3390/ijms17060932
Cruz-Jentoft AJ, Woo J (2019) Nutritional interventions to prevent and treat frailty. Curr Opin Clin Nutr Metab Care 22(3):191–195
Long DE, Peck BD, Martz JL, Tuggle SC, Bush HM, McGwin G et al (2017) Metformin to augment strength training effective response in seniors (MASTERS): study protocol for a randomized controlled trial. Trials 18(1):192. https://doi.org/10.1186/s13063-017-1932-5
Zhang YJ, Wang JX, Fu SH, Li XY (2019) Trimetazidine in angina and poor muscle function: protocol for a randomized controlled study. Chin Med J 132(12):1461–1466
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Guest, P.C. (2020). The Impact of New Biomarkers and Drug Targets on Age-Related Disorders. In: Guest, P. (eds) Clinical and Preclinical Models for Maximizing Healthspan. Methods in Molecular Biology, vol 2138. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0471-7_1
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0471-7_1
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0470-0
Online ISBN: 978-1-0716-0471-7
eBook Packages: Springer Protocols